Citigroup Inc Next Cure, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Next Cure, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1,419,370 shares of NXTC stock, worth $681,297. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,419,370
Previous 1,389,040
2.18%
Holding current value
$681,297
Previous $1.07 Million
36.3%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NXTC
# of Institutions
38Shares Held
13.7MCall Options Held
1.7KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$1.28 Million0.09% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.3MShares$1.11 Million0.12% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$547,7760.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$473,9150.0% of portfolio
-
Black Rock Inc. New York, NY761KShares$365,3660.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $13.3M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...